



RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS

Milan, 20th June 2022 – Recordati S.p.A. (the "Company") informs that, in execution of the resolution adopted by the Shareholders' meeting held on 29th April 2022, it has granted a mandate to UBS Europe SE to launch today – in full independency, in compliance with applicable legislation and the provisions of the shareholders' meeting resolution - a share buy-back program under art. 5 of (EU) Regulation no. 596/2014 and (EU) delegated Regulation no. 1052/2016 (the "Program"), on behalf of the Company.

The details of the Program are the following:

- **Purpose of the Program:** the Program involves the acquisition of Recordati ordinary shares to service current and future stock option plans in favour of the Recordati Group's management or share-based incentive plans that should be approved by the Company in the future.
- Maximum number of shares: the acquisition could involve a maximum of up to 1,000,000 ordinary nominal value Eur 0.125 Recordati shares and, in any case, within the legal limit (1/5 of the company's entire share capital as established by art. 2357, paragraph 3 of the Italian Civil Code), including any shares owned by the Company.
 - As of 17th June 2022, the Company had no. 3,431,802 shares in Treasury stock which amounts to 1.6410% of the share capital.
- Minimum and maximum consideration payable and maximum cash outlay: the minimum purchase price for the ordinary shares shall not be lower than the share's nominal value (Eur 0.125) while the maximum purchase price shall not exceed the lower of the average official Stock Exchange price recorded over the 5 trading days prior to the transaction and the average official Stock Exchange price recorded over the 20 trading days prior to the transaction, plus 5%, within the maximum cash outlay of Eur 50 million (fifty million).
- **Duration:** until 14th April 2023; please be reminded that the expiry of the authorization granted by the Shareholders' meeting held on 29th April 2022 is until the approval by the Shareholders' meeting of the 2022 financial statements.
- Buyback procedures: in compliance with art. 132 of the Legislative Decree 58/1998 and art. 144-bis, paragraph 1, letter b) of the Issuers Regulation, as well as in compliance with (EU) Regulation 596/2014 of 16th April 2014 and its relative implementing provisions (also with reference to the purchase price and the daily volume allowed) and in line with the authorization of the Shareholders' Meeting.

Any subsequent changes to the programme will be promptly disclosed to the public according to the conditions and deadlines set forth by the applicable law.

The operations carried out will be disclosed to the market according to the deadlines and conditions set forth by the regulatory provisions currently in force.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1 Share Capital € 26.140.644,50 fully paid-up

20148 Milano, Italy Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150

Ph. (39) 02 487871 Tax Code/VAT No. 00748210150 Fax (39) 02 40073747 Milano R.E.A. No. 401832

www.recordati.com



and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was € 1,580.1 million, operating income was € 490.2 million and net income was € 386.0 million.

For further information:

Recordati website: www.recordati.it

<u>Investor Relations</u> <u>Investor Relations</u> <u>Media Relations</u>

Federica De Medici Lucia Abbatantuoni Brunswick: Barbara Scalchi / Andrea Mormandi

(39) 02 48787146 (39) 02 48787213 (39) 02 9288 6200

e-mail: investorelations@recordati.it e-mailto: investorelations@recordati.it e-mailto: investorelations e-mailto: <a href="mailto:investorelatio

This document contains forward-looking statements relating to future events and future operating, economic and financial results of the Recordati group. By their nature, forward-looking statements involve risk and uncertainty because they depend on the occurrence of future events and circumstances. Actual results may therefore differ materially from those forecast as a result of a variety of reasons, most of which are beyond the Recordati group's control. The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the Recordati group's activities and therefore, as such, it is not intended as medical scientific indication or recommendation, nor as advertising.